{"id":581606,"date":"2022-01-11T17:32:01","date_gmt":"2022-01-11T17:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=581606"},"modified":"2022-01-11T17:32:01","modified_gmt":"2022-01-11T17:32:01","slug":"scleroderma-pipeline-drugs-and-companies-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/scleroderma-pipeline-drugs-and-companies-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_581606.html","title":{"rendered":"Scleroderma Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1641873145.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Scleroderma Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1641873145.jpeg\" alt=\"Scleroderma Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Scleroderma Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>&lsquo;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Scleroderma Pipeline Insights<\/strong><\/a><strong>&rsquo;<\/strong>&nbsp;report lays down a holistic coverage of the available therapies, Scleroderma pipeline therapies in different developmental phases of clinical trials, key companies active in the Scleroderma pipeline domain, driving factors and restraints in the commercial launch of the Scleroderma pipeline therapies, and future trends.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights from the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Scleroderma Pipeline<\/a>&nbsp;report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s analysis depicts a robust Scleroderma Pipeline with&nbsp;<strong>50+ active players&nbsp;<\/strong>in the domain working on&nbsp;<strong>50+ pipeline therapies<\/strong>.&nbsp;<\/li>\n<li>Key Scleroderma pipeline therapies such as&nbsp;<strong>Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab,<\/strong>&nbsp;<strong>ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200&nbsp;<\/strong>and others are under evaluation in different phases of clinical trials for the treatment of Scleroderma.&nbsp;<\/li>\n<li><strong>Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio&nbsp;<\/strong>among several others are key prominent pharma companies working in the domain.&nbsp;<\/li>\n<li>In January 2021, Timber Pharmaceuticals received Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis.<\/li>\n<li>CiVi 030 is an intravenous formulation of iloprost, a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc). CiVi 030 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Systemic Sclerosis (SSc).<\/li>\n<li>In April 2020, Horizon Therapeutics announced that it had acquired Curzion Pharmaceuticals and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825), for the treatment of Systemic Sclerosis.<\/li>\n<li><strong>FCX-013<\/strong>&nbsp;is being developed as a disease-modifying, autologous cell-based gene therapy that utilizes lentiviral vectors to deliver functional matrix metalloproteinase 1 genes (MMP-1) to patients with moderate to severe localized Scleroderma.<\/li>\n<li>The U. S. Food and Drug Administration has granted Orphan Drug designation to FCX-013 for the treatment of localized Scleroderma. In addition, FCX-013 has been granted Rare Pediatric Disease designation and Fast Track designation for the treatment of moderate to severe localized Scleroderma.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample to know which pharma company is expected to be at the forefront in the coming years @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/scleroderma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Scleroderma Emerging Therapies and Forecast&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Scleroderma Pipeline report comprises detailed information on ongoing clinical trials, deals, mergers &amp; acquisitions taking place in the domain, recent approvals and failures in space, and growth prospects across the Scleroderma domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scleroderma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Scleroderma is a group of rare diseases that leads to the hardening and tightening of the skin and connective tissues. There are 2 major types of Scleroderma: Localized Scleroderma that affects the skin and Systemic Scleroderma that affects blood circulation and internal organs as well as the skin. The condition appears to affect women more as compared to men. At present, there exists no cure for the disease; however, there are symptomatic treatment approaches available.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about the disease, treatments, and pipeline therapies @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/scleroderma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Scleroderma Pipeline Assessment&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scleroderma Pipeline Drugs&nbsp;<\/strong><\/p>\n<table style=\"width: 0px;\" border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p><strong>Drug<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Company<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Phase<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>MoA<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>RoA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Lenabasum<\/strong><\/p>\n<\/td>\n<td>\n<p>Corbus Pharmaceuticals<\/p>\n<\/td>\n<td>\n<p>III<\/p>\n<\/td>\n<td>\n<p>Cannabinoid receptor CB2 agonists<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Iloprost<\/strong><\/p>\n<\/td>\n<td>\n<p>Eicos Sciences<\/p>\n<\/td>\n<td>\n<p>III<\/p>\n<\/td>\n<td>\n<p>Epoprostenol agonists<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>KHK4827<\/strong><\/p>\n<\/td>\n<td>\n<p>Kyowa Kirin<\/p>\n<\/td>\n<td>\n<p>III<\/p>\n<\/td>\n<td>\n<p>Interleukin 17 receptor antagonists<\/p>\n<\/td>\n<td>\n<p>Subcutaneous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>ECCS-50<\/strong><\/p>\n<\/td>\n<td>\n<p>Cytori therapeutics<\/p>\n<\/td>\n<td>\n<p>III<\/p>\n<\/td>\n<td>\n<p>Cell replacements<\/p>\n<\/td>\n<td>\n<p>Subcutaneous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>EHP 101<\/strong><\/p>\n<\/td>\n<td>\n<p>Emerald Health Pharmaceuticals<\/p>\n<\/td>\n<td>\n<p>II<\/p>\n<\/td>\n<td>\n<p>Cannabinoid receptor CB2 agonists; Endothelial PAS domain-containing protein 1 inhibitors; Hypoxia-inducible factor 1 inhibitors; Peroxisome proliferator-activated receptor-gamma agonists<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>FT011<\/strong><\/p>\n<\/td>\n<td>\n<p>Certa Therapeutics<\/p>\n<\/td>\n<td>\n<p>II<\/p>\n<\/td>\n<td>\n<p>Platelet-derived growth factor inhibitors<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Belumosudil<\/strong><\/p>\n<\/td>\n<td>\n<p>Kadmon Corporation<\/p>\n<\/td>\n<td>\n<p>II<\/p>\n<\/td>\n<td>\n<p>Rho-associated kinase inhibitors<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>Guselkumab<\/strong><\/p>\n<\/td>\n<td>\n<p>Janssen Pharmaceutical<\/p>\n<\/td>\n<td>\n<p>II<\/p>\n<\/td>\n<td>\n<p>Interleukin-23 subunit p19 inhibitors<\/p>\n<\/td>\n<td>\n<p>Intravenous, Subcutaneous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>FCX 013<\/strong><\/p>\n<\/td>\n<td>\n<p>Castle Creek Biosciences<\/p>\n<\/td>\n<td>\n<p>I\/II<\/p>\n<\/td>\n<td>\n<p>Gene transference; Matrix metalloproteinase 1 replacements<\/p>\n<\/td>\n<td>\n<p>Intradermal<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>VIB7734<\/strong><\/p>\n<\/td>\n<td>\n<p>Viela Bio<\/p>\n<\/td>\n<td>\n<p>I<\/p>\n<\/td>\n<td>\n<p>Dendritic cell inhibitors<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>CM-101<\/strong><\/p>\n<\/td>\n<td>\n<p>Chemomab Therapeutics<\/p>\n<\/td>\n<td>\n<p>I<\/p>\n<\/td>\n<td>\n<p>Chemokine CCL24 inhibitors<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>AM1476<\/strong><\/p>\n<\/td>\n<td>\n<p>AnaMar<\/p>\n<\/td>\n<td>\n<p>I<\/p>\n<\/td>\n<td>\n<p>Serotonin 2B receptor antagonists<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>LMY-920<\/strong><\/p>\n<\/td>\n<td>\n<p>Luminary Therapeutics<\/p>\n<\/td>\n<td>\n<p>Preclinical<\/p>\n<\/td>\n<td>\n<p>Immunologic cytotoxicity; T lymphocyte replacements<\/p>\n<\/td>\n<td>\n<p>Parenteral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>CAN-10<\/strong><\/p>\n<\/td>\n<td>\n<p>Cantargia<\/p>\n<\/td>\n<td>\n<p>Preclinical&nbsp;<\/p>\n<\/td>\n<td>\n<p>Interleukin 1 inhibitors; Interleukin-33 inhibitors<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>hzVSF v13<\/strong><\/p>\n<\/td>\n<td>\n<p>ImmuneMed<\/p>\n<\/td>\n<td>\n<p>Discovery<\/p>\n<\/td>\n<td>\n<p>Immunomodulators; Virus replication inhibitors<\/p>\n<\/td>\n<td>\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request for Sample to know more @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/scleroderma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Scleroderma Pipeline Analysis, Key Companies, and Futuristic Trends&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scleroderma Therapeutics Assessment&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The&nbsp;Scleroderma Pipeline&nbsp;report proffers an integral view of the Scleroderma emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.<\/p>\n<p style=\"text-align: justify;\"><strong>By Product Type<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mono<\/li>\n<li>Combination<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Stage<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Discovery&nbsp;<\/li>\n<li>Pre-clinical<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Molecule Type<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Intravenous<\/li>\n<li>Intradermal<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Mechanism of Action<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Collagen inhibitors; Cytokine inhibitors<\/li>\n<li>Dendritic cell inhibitors<\/li>\n<li>Serotonin 2B receptor antagonists<\/li>\n<li>Chemokine CCL24 inhibitors<\/li>\n<li>Platelet-derived growth factor inhibitors<\/li>\n<li>Gene transference; Matrix metalloproteinase 1 replacement<\/li>\n<li>Cell replacements<\/li>\n<li>Interleukin 1 inhibitors; Interleukin-33 inhibitors<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Targets<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Proteins<\/li>\n<li>Replication pathways<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the&nbsp;Scleroderma Drug Pipeline&nbsp;Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Coverage<\/strong>: Global<\/p>\n<p style=\"text-align: justify;\"><strong>Key Players<\/strong>: Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio among others.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Scleroderma Pipeline Therapies<\/strong>: Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab, ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200 and several others.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table style=\"width: 460px;\" border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1<\/p>\n<\/td>\n<td>\n<p>Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2<\/p>\n<\/td>\n<td>\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3<\/p>\n<\/td>\n<td>\n<p>Scleroderma Disease Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4<\/p>\n<\/td>\n<td>\n<p>Scleroderma Pipeline Therapeutics Comparative Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5<\/p>\n<\/td>\n<td>\n<p>Scleroderma Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6<\/p>\n<\/td>\n<td>\n<p>In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7<\/p>\n<\/td>\n<td>\n<p>Scleroderma &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8<\/p>\n<\/td>\n<td>\n<p>In-depth Commercial Scleroderma Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9<\/p>\n<\/td>\n<td>\n<p>Scleroderma Collaboration Deals&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10<\/p>\n<\/td>\n<td>\n<p>Late Stage Scleroderma Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.1<\/p>\n<\/td>\n<td>\n<p>Lenabasum: Corbus Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11<\/p>\n<\/td>\n<td>\n<p>Mid-Stage Scleroderma Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.1<\/p>\n<\/td>\n<td>\n<p>EHP 101: Emerald Health Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12<\/p>\n<\/td>\n<td>\n<p>Early Stage Scleroderma Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.1<\/p>\n<\/td>\n<td>\n<p>VIB7734: Viela Bio<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13<\/p>\n<\/td>\n<td>\n<p>Pre-clinical and Discovery Stage Scleroderma Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.1<\/p>\n<\/td>\n<td>\n<p>LMY-920: Luminary Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14<\/p>\n<\/td>\n<td>\n<p>Inactive Scleroderma Pipeline Products&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15<\/p>\n<\/td>\n<td>\n<p>Key Scleroderma Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16<\/p>\n<\/td>\n<td>\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17<\/p>\n<\/td>\n<td>\n<p>Scleroderma Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18<\/p>\n<\/td>\n<td>\n<p>Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19<\/p>\n<\/td>\n<td>\n<p>Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20<\/p>\n<\/td>\n<td>\n<p>Key Scleroderma Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;<strong>PharmDelve<\/strong>.<\/p>\n<p style=\"text-align: justify;\">For more insights, visit&nbsp;<strong>Pharma, Healthcare, and Biotech News&nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=scleroderma-pipeline-drugs-and-companies-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/scleroderma-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=scleroderma-pipeline-drugs-and-companies-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scleroderma Pipeline DelveInsight&rsquo;s&nbsp;&lsquo;Scleroderma Pipeline Insights&rsquo;&nbsp;report lays down a holistic coverage of the available therapies, Scleroderma pipeline therapies in different developmental phases of clinical trials, key companies active in the Scleroderma pipeline domain, driving factors and restraints in the commercial launch &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/scleroderma-pipeline-drugs-and-companies-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_581606.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-581606","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/581606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=581606"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/581606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=581606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=581606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=581606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}